Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

K Jonstam, BN Swanson, LP Mannent, LO Cardell… - Allergy, 2019 - Wiley Online Library
Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2‐mediated
inflammatory disease associated with significant clinical, social, and economic burdens and
high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the
interleukin‐4 receptor α (IL‐4Rα) subunit, demonstrated efficacy and acceptable safety in
CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the
local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal …

Biomarkers in chronic rhinosinusitis with nasal polyps

AD Workman, MA Kohanski… - … and Allergy Clinics, 2018 - immunology.theclinics.com
Chronic rhinosinusitis (CRS) is a prevalent and heterogeneous disease associated with a
high degree of morbidity. Although there exist specific conditions for diagnosis, it has been
increasingly appreciated that CRS exists as a spectrum of clinical conditions with distinct
pathophysiology and presentation. 1 Targeted biologics for treating asthma are now being
used for CRS with nasal polyps (CRSwNP), which has a Department of Otorhinolaryngology–
Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman …